SCI Abstract

search
+
The therapeutic potential of exosomes in bone cancers: osteosarcoma, chondrosarcoma, and Ewing sarcoma
The therapeutic potential of exosomes in bone cancers: osteosarcoma, chondrosarcoma, and Ewing sarcoma
Osteosarcoma (OS), chondrosarcoma (CHS), and Ewing sarcoma (EwS) are the most common primary bone cancers (BCs). Among pri...
Targeting neuroblastoma with hydroxamic acid based HDAC1 and HDAC2 inhibitors: Insights from in vitro and in vivo studies
Targeting neuroblastoma with hydroxamic acid based HDAC1 and HDAC2 inhibitors: Insights from in vitro and in vivo studies
Histone deacetylases (HDACs) serve a crucial function in transcription regulation, and their dysregulation is linked to nu...
Safety and pharmacokinetics of FCN-437c, a novel cyclin-dependent kinase 4/6 inhibitor, in Chinese patients with hepatic impairment
Safety and pharmacokinetics of FCN-437c, a novel cyclin-dependent kinase 4/6 inhibitor, in Chinese patients with hepatic impairment
This study explored the impact of hepatic impairment on the safety and pharmacokinetics (PK) of FCN-437c, a novel dual CDK...
Low-dose PD-1 inhibition in relapsed/refractory classic Hodgkin lymphoma: systematic review and meta-analysis
Low-dose PD-1 inhibition in relapsed/refractory classic Hodgkin lymphoma: systematic review and meta-analysis
No correlation between the dose, adverse events, and efficacy was detected in clinical trials of anti-PD-1 antibodies acro...
Addressing the drug development challenge for rare pediatric diseases in Japan: a case study of isotretinoin
Addressing the drug development challenge for rare pediatric diseases in Japan: a case study of isotretinoin
Drug lag in rare pediatric diseases remains a significant challenge in Japan despite its sophisticated healthcare system. ...
Design and optimization of PLGA-based gemcitabine nanocapsule for enhanced pancreatic cancer efficacy
Design and optimization of PLGA-based gemcitabine nanocapsule for enhanced pancreatic cancer efficacy
This study aimed to develop gemcitabine-loaded nanocapsules for pancreatic cancer treatment, optimizing their formulation ...
Comparative analysis of engineered-exosome delivered si-HER2 and trastuzumab in the treatment of HER2-positive gastric cancer
Comparative analysis of engineered-exosome delivered si-HER2 and trastuzumab in the treatment of HER2-positive gastric cancer
Trastuzumab is currently a key targeted drug for HER2-positive gastric cancer (GC), but there are common problems of drug ...
Clinical features, treatment and outcomes of dabrafenib-associated uveitis
Clinical features, treatment and outcomes of dabrafenib-associated uveitis
To explore the clinical characteristics of dabrafenib-associated uveitis and provide a basis for diagnosis and treatment. ...
Pharmacokinetics, efficacy and safety of palbociclib and fulvestrant in a patient with hormone receptor-positive, human epidermal growth factor receptor 2 negative metastatic breast cancer with end-stage renal disease undergoing hemodialysis: A case report
Pharmacokinetics, efficacy and safety of palbociclib and fulvestrant in a patient with hormone receptor-positive, human epidermal growth factor receptor 2 negative metastatic breast cancer with end-stage renal disease undergoing hemodialysis: A case report
Palbociclib combined with fulvestrant is a standard treatment for hormone receptor-positive, human epidermal growth factor...
Synergistic effects of the curcumin analog HO-3867 and olaparib in transforming fallopian tube epithelial cells
Synergistic effects of the curcumin analog HO-3867 and olaparib in transforming fallopian tube epithelial cells
Ovarian cancer remains one of the most lethal gynecologic malignancies, largely due to high recurrence rates and treatment...
Direct functional HOXA9/DNA-binding competitors versus epigenetic inhibitors of HOXA9 expression on cell proliferation, death and differentiation processes in the model of MLL-rearranged acute myeloid leukemia
Direct functional HOXA9/DNA-binding competitors versus epigenetic inhibitors of HOXA9 expression on cell proliferation, death and differentiation processes in the model of MLL-rearranged acute myeloid leukemia
Recent progress in cancer treatment has led to the development of advanced therapies targeting specific oncogenic drivers,...
Anti-CD47 tri-specific killer engager enhances NK cell cytotoxicity against lung cancer
Anti-CD47 tri-specific killer engager enhances NK cell cytotoxicity against lung cancer
Lung cancer remains the leading cause of cancer-related deaths worldwide, with immune evasion posing a major therapeutic c...
Clinical characteristics, treatment and prognosis of pembrolizumab induced myocarditis
Clinical characteristics, treatment and prognosis of pembrolizumab induced myocarditis
To explore the regularity and clinical characteristics of pembrolizumab induced myocarditis, and to provide a reference fo...
The multifaceted role of KIF15 in cancer progression and therapy
The multifaceted role of KIF15 in cancer progression and therapy
Kinesin family member 15 (KIF15), a kinesin superfamily motor protein, is known to be involved in mitotic spindle formatio...
Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor–relapsed tumors
Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor–relapsed tumors
We report a phase 1/2 study evaluating EDP1503 (capsule containing Bifidobacterium animalis lactis) ± pem...
Tackling tumor hypoxia: advances in breaking the oncogenic HIF-1α–p300/CBP alliance
Tackling tumor hypoxia: advances in breaking the oncogenic HIF-1α–p300/CBP alliance
The ability of tumor cells to survive under low-oxygen conditions is largely attributed to the hypoxia-inducible factor-1 ...
Assessing the risks and benefits of investigational new drugs in adult phase-I oncology trials in China, 2013–2021
Assessing the risks and benefits of investigational new drugs in adult phase-I oncology trials in China, 2013–2021
Previous research shows that the benefits of phase-I oncology trials increased from 5 to 18% between 2000 and 2019 globall...
Clinical potential of antibody–drug conjugates in early-phase clinical trials for late-line treatment of advanced solid tumors
Clinical potential of antibody–drug conjugates in early-phase clinical trials for late-line treatment of advanced solid tumors
Recently, comprehensive genomic profiling (CGP)-matched therapy and antibody–drug conjugates (ADCs) have garnered in...
Beyond the obvious: targeting the SLC transportome and non-canonical drug transport mechanisms in cancer therapy
Beyond the obvious: targeting the SLC transportome and non-canonical drug transport mechanisms in cancer therapy
The solute carrier (SLC) superfamily comprises a broad array of membrane-bound transport proteins that are integral to the...
Efficacy of immune checkpoint inhibitor rechallenge in initial immunotherapy responders with advanced non-small cell lung cancer: A single-center retrospective study
Efficacy of immune checkpoint inhibitor rechallenge in initial immunotherapy responders with advanced non-small cell lung cancer: A single-center retrospective study
Background: The efficacy of immune rechallenge in patients with advanced non-small cell lung cancer (NSCLC) who responded ...
Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models
Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models
Ovarian cancer is the fifth leading cause of cancer related death in the United States. Cisplatin is a platinum-based anti...
Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial
Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial
The reporting of adverse events (AEs) is fundamental to characterize safety profiles of novel therapeutic drug classes, ho...
Comprehensive study of gene fusions in sarcomas
Comprehensive study of gene fusions in sarcomas
Sarcomas, including bone sarcomas and soft tissue sarcomas (STSs), are a heterogeneous group of mesenchymal malignancies. ...
Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study
Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study
Currently, therapeutic combinations of immune checkpoint inhibitors (ICIs) with anti-angiogenic agents have shown promisin...
5-Fluorouracil-methotrexate conjugate enhances the efficacy of 5-fluorouracil in colorectal cancer therapy
5-Fluorouracil-methotrexate conjugate enhances the efficacy of 5-fluorouracil in colorectal cancer therapy
To extend the short half-life of fluorouracil (Fu), enhance its tumor targeting, improve efficacy, and reduce side effects...
Clinical features, treatment, and outcomes of nivolumab induced psoriasis
Clinical features, treatment, and outcomes of nivolumab induced psoriasis
Psoriasis is an uncommon immune-mediated adverse event linked to nivolumab, and its clinical characteristics remain inadeq...
Deficiency of myeloid discoidin domain receptor 2 aggravates melanoma lung and bone metastasis
Deficiency of myeloid discoidin domain receptor 2 aggravates melanoma lung and bone metastasis
Melanoma, one of the most prevalent cancers worldwide, frequently metastasizes to the lung and bones. Tumor-associated mac...
A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer
A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer
Antiangiogenic drugs may cause vascular normalization and correct hypoxia in tumors, shifting cells to mitochondrial respi...
Efficacy and safety of multi-target tyrosine kinase inhibitor AL2846 combined with gemcitabine in pancreatic cancer
Efficacy and safety of multi-target tyrosine kinase inhibitor AL2846 combined with gemcitabine in pancreatic cancer
Pancreatic cancer patients urgently need new treatments, and we explored the efficacy and safety of combination therapy wi...
Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA
Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA
The impact of clinical stage on the effectiveness of osimertinib for epidermal growth factor receptor (EGFR) mutation-posi...
Load More
format_indent_increase